From multivariable analysis, predictors of LP were male gender (OR=18.2, P < 0.0001), diarrhea (OR = 3.7, P = 0.05), BMI (OR = 1.2, P = 0.05) and CWIC score (OR = 0.57, P = 0.004). Patients with SP were more likely to require intubation (P = 0.04), an ICU stay (P = 0.004) and to die (P = 0.002).
Conclusion.
Our data suggest that high temperature and diarrhea may be used to help differentiate LP and SP pneumonia. The higher incidence among men requires further investigation. LP demonstrated a higher morbidity and mortality than SP.
Disclosures. Background. Community acquired pneumonia (CAP) is one of the leading causes of death in the United States. While most data regarding management of CAP comes from management of hospitalized patients, the majority of CAP cases are actually managed on an outpatient basis. The primary outcome of this study was to determine the incidence of appropriate diagnosis (based on Infectious Diseases Society of America (IDSA) guidelines) and appropriate treatment regimens, to identify potential stewardship targets in outpatients treated for CAP.
Methods. Patients were identified by ICD-9/10 codes for CAP. Patients were seen in the Veterans Affairs Western New York Healthcare System which consists of the emergency room, and local, home-based and rural clinics between January 2008 and January 2018. Those who were treated appropriately and those who were not were compared using Student's t-test or chi-square tests.
Results. This study included 518 veterans with CAP. Sixty-six percent of veterans were deemed appropriate to treat. Of the 341 patients who had an appropriate diagnosis of CAP, 31% received an appropriate antibiotic regimen. Of those who were appropriate to treat, 76.7% received an incorrect drug based on comorbidities, 5.1% received an inappropriate dose, and 39.4% received an incorrect duration. Azithromycin was most commonly prescribed (45%) followed by a respiratory fluoroquinolone (38%) and doxycycline (10%). Patients with risk factors for drug-resistant Streptococcus pneumoniae (DRSP) were more likely to be deemed appropriate to treat (81% vs. 66%, P = 0.002); however, they were less likely to receive an appropriate antibiotic regimen (64% vs. 88%; P < 0.0001). Being appropriate to treat was more likely with pneumococcal vaccinations PCV13 (35% vs. 15%, P < 0.0001) and/or PPSV23 (72% vs. 59%, P = 0.003). A minority of patients re-presented within 30 days for CAP (4.1%); however, they were more likely to re-present if they had radiographic evidence of CAP on imaging (90.5%, P = 0.03) and were considered appropriate to treat (91%, P = 0.02).
Conclusion. Improvement in prescribing is needed in the outpatient setting for CAP. A stewardship program could target patients with risk factors for DRSP to improve compliance with the IDSA guidelines by ensuring appropriate antibiotic regimens.
Disclosures. Methods. This retrospective cohort included pediatric patients diagnosed with CAP and received initial empiric antibiotics after presenting to the institution. The cohorts were categorized as fully immunized or not fully immunized consistent with state immunization health records and national recommendations according to the child's age. The primary outcome was receipt of appropriate vs. inappropriate antibiotics according to guideline recommendations. Multivariable analyses were used to evaluate inappropriate empiric antibiotics for CAP with immunizations status as exposure of interest. Secondary outcomes included length of stay and 30-day readmission rates.
Results. A total of 189 patients (129 fully immunized and 60 not fully-immunized) were included in the interim analysis. A total of 104 patients (55%) received inappropriate antibiotics [62 of the fully immunized (48%) and 42 of the not fully immunized (70%) received inappropriate antibiotics (P = 0.0048)]. Multivariable analysis identified not fully-immunized and age as independent predictors for inappropriate empiric antibiotics for CAP, aOR 2.77, 95% CI (1.20, 5.89), P = 0.008, and aOR 1.41, 95% CI (1.15, 1.72), P = 0.001; respectively. In terms of secondary outcomes, not fully-immunized patients had longer length of stay, higher readmission in 30 days, and greater need for oxygen supplementation, but none of these results were statistically significant.
Conclusion. Currently, the majority of pediatric patients treated for CAP received inappropriate empiric antibiotics. Not fully-immunized patients were more likely to receive inappropriate empiric antibiotics for CAP and subsequently did not have improved morbidity.
Disclosures. All authors: No reported disclosures.
Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
Owen Albin, MD 1 ; Oryan Henig, MD Background. Microbiologic cure is a frequent outcome in pneumonia trials, but its clinical relevance remains poorly understood. We aimed to evaluate the association between microbiologic failure in pneumonia in the setting of clinical cure and recurrent pneumonia and mortality.
Methods. Retrospective, single-center cohort study of adult patients hospitalized between January 1, 2008 and January 1, 2017. Patients with index pneumonia (defined as a positive respiratory culture and continuous receipt of ≥5 days of antibiotics) who demonstrated clinical cure (defined as cessation of all antibiotics for ≥48 hours and survival for 7 days following antibiotic completion) were included. All included patients had to have follow-up respiratory cultures obtained between 3 days before and 7 days after completion of antibiotic therapy. Patients with persistence of the inciting pathogen were classified as microbiologic failure and all others as microbiologic cure. Primary outcomes were 30-day mortality and a 30-day composite of mortality and/or recurrent pneumonia.
Results. Of 376 included patients, 61% had microbiologic cure compared with 39% with microbiologic failure. Mean age was 55.4 years, 62% of patients were male and 79% White. Mean antibiotic duration was 14.8 days. Sixty-one percent of patients were mechanically ventilated at the time of index pneumonia. The most common pathogens were Enterobacteriaceae (35%), Staphylococcus aureus (31%) and Pseudomonas aeruginosa (22%). In the microbiologic failure group, the primary composite outcome occurred in 18.9% of patients compared with 11.8% in the microbiologic cure group (OR 1.73, 95% CI 0.98-3.09) (Figure 1 ). All-cause 30-day mortality was greater in patients with microbiologic failure (16.2%) than microbiologic cure (8.3%) (OR 2.13, 95% CI 1.12-4.04). These associations were particularly strong among nonventilated patients (Figure 2 ). Rates of recurrent pneumonia were similar between groups.
Conclusion. Patients with clinical cure but microbiologic failure were more than twofold more likely to die 30 days after their index pneumonia than those with microbiologic cure. Patients with microbiologic failure who were not mechanically ventilated at the time of index pneumonia had a greater than fourfold increased mortality risk. 
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